Mycoplasma Testing Market to Grow with a CAGR of 13.51% through 2031

Increase in the advancement of biotechnology and growing healthcare infrastructure is expected to drive the Global Mycoplasma Testing Market growth in the forecast period, 2027-2031.

According to TechSci Research's report, “Mycoplasma Testing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2031F,” the global mycoplasma testing market is projected to grow from USD 1097.92 million in 2025 to USD 2348.42 million by 2031, at a 13.51% CAGR.

The increasing awareness of mycoplasma-related infections across human and animal health is creating favorable market conditions for the global mycoplasma testing industry. As healthcare professionals, researchers, and industries recognize the health risks, economic consequences, and transmission pathways associated with mycoplasma contamination, demand for accurate and reliable testing solutions continues to rise. This growing awareness has positioned mycoplasma testing as an essential tool for disease detection, prevention, and quality control, further accelerating market expansion.

The life sciences sector has experienced a surge in research and development (R&D) across fields such as genomics, proteomics, and drug discovery, all of which rely heavily on cell culture and biotechnological processes. However, mycoplasma contamination poses a serious threat to experimental integrity and biopharmaceutical production, leading to potential financial losses and compromised scientific outcomes. As R&D activities expand globally, demand for robust mycoplasma testing solutions is increasing, ensuring research accuracy and safeguarding biopharmaceutical manufacturing. In biopharmaceutical production, as demand for innovative biologics and cell-based therapies increases rapidly, contamination risks remain a major concern. The presence of mycoplasma in biologic products can compromise both safety and efficacy, leading to regulatory setbacks, financial losses, and potential harm to patients. With the industry experiencing unprecedented growth, mycoplasma testing has become an essential quality-control measure to maintain product integrity and patient safety.

The rapid advances in genomics, proteomics, and drug discovery have transformed the life sciences industry, making high-precision mycoplasma testing integral to modern research. Ensuring cell culture purity is critical for generating reproducible and reliable results, making fast and accurate mycoplasma detection technologies indispensable. In an increasingly competitive scientific landscape, validated and contamination-free experimental data is essential for driving breakthroughs. The rising emphasis on personalized medicine has further strengthened the role of mycoplasma testing in clinical diagnostics. Early detection of mycoplasma infections is crucial for effective disease management, as undiagnosed contamination can lead to severe patient outcomes. Healthcare providers are increasingly adopting rapid mycoplasma detection methods to enable early intervention and precise treatment decisions, improving patient care and therapeutic efficacy.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Mycoplasma Testing Market”

The Global Mycoplasma Testing Market is segmented by product, application, technology, end user, region, and company.

Within the Application category, the cell line testing segment accounted for the largest share of the global Mycoplasma Testing market in 2024. Mycoplasma contamination poses a significant threat to biopharmaceutical manufacturing. It can compromise product safety and efficacy, leading to costly production delays and product recalls. Biopharmaceutical companies prioritize mycoplasma testing for their cell lines to ensure the integrity of their products. The consequences of contamination make cell line testing a non-negotiable step in manufacturing.

Regulatory agencies, including the FDA and EMA, have stringent guidelines for mycoplasma testing in biopharmaceutical manufacturing. Compliance with these regulations is mandatory. To gain regulatory approval and maintain product quality, biopharmaceutical companies must conduct rigorous mycoplasma testing for cell lines. This requirement drives the demand for testing services and products in this segment. Mycoplasma contamination can skew research results and invalidate experiments, leading to wasted time and resources. Research laboratories, especially those working on cell-based experiments, prioritize mycoplasma testing to ensure the accuracy and reliability of their findings. Cell line testing is integral to maintaining research quality. Detecting mycoplasma contamination early is crucial. It allows for prompt intervention and minimizes the risk of contamination spread. Cell line testing's ability to provide rapid results ensures timely detection and mitigation of mycoplasma contamination, preventing its escalation within manufacturing facilities and research environments. Mycoplasma contamination can lead to batch loss, production delays, and the need for costly decontamination procedures. Biopharmaceutical companies invest in routine cell line testing as a proactive measure to prevent contamination-related disruptions. This preventive approach safeguards production schedules and reduces financial losses.

Based on region, The Asia Pacific region is anticipated to experience a remarkable Compound Annual Growth Rate (CAGR). This growth can be attributed to rising healthcare expenditure and increasing demand for enhanced laboratory and clinical research infrastructure. Moreover, regulatory policies established by healthcare institutions to improve biosafety standards are expected to create substantial growth prospects. Additionally, emerging markets such as India are presenting promising opportunities in this sector. The Indian government's proactive initiatives to stimulate research and innovation for the development of new medications are driving market expansion.

Major companies operating in Global Mycoplasma Testing Market are:

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

Download Free Sample Report

Customers may also request a 10% discount on this report.

“The advancement in biopharmaceutical and increasing Disease Awareness are key drivers of the Mycoplasma Testing market. In recent years, innovations in mycoplasma testing methodologies, such as PCR-based techniques and rapid testing kits, have driven market growth by providing faster and more accurate results. Moreover, the growing consumer emphasis on preventative healthcare products has enhanced production and marketing efforts. To meet market demands, manufacturers are increasingly incorporating advanced technologies to enhance production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the Mycoplasma Testing and supplements market in the coming years.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Mycoplasma Testing Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product (Instruments, Kits and Reagents), By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other), By Application (Cell Line Testing, Bioproduction Testing, Other), By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others), By Region, Competition, 2021-2031F", has evaluated the future growth potential of Global Mycoplasma Testing Market and provides statistics & information on market size, structure and future market growth. The report aims to provide cutting-edge market intelligence and help decision-makers make sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Mycoplasma Testing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com